JIANGSU

EQS-News: Schweizer Electronic AG: Business development in the first quarter

Retrieved on: 
Friday, May 10, 2024
Depreciation, Tax, EUR, Schramberg, Film industry

Schramberg, May 8, 2024 – The sales of the SCHWEIZER Group amounted to EUR 39.2 million in the first quarter of 2024 (Q1 2023: EUR 37.1 million).

Key Points: 
  • Schramberg, May 8, 2024 – The sales of the SCHWEIZER Group amounted to EUR 39.2 million in the first quarter of 2024 (Q1 2023: EUR 37.1 million).
  • The first quarter of 2023 still included a revenue of EUR 1.8 million from the associated company Schweizer Electronic (Jiangsu) Co, Ltd, China (“SEC”).
  • Sales to Automotive customers amounted to EUR 31.3 million (Q1 2023: EUR 24.9 million), which corresponds to an increase of +25.7% compared to the first quarter of 2023.
  • The order backlog was EUR 224.9 million at the end of the quarter (December 31, 2023: EUR 251.3 million).

Boyu to Showcase Cutting-Edge SPC Flooring Production Lines at NPE2024

Retrieved on: 
Sunday, May 5, 2024
SPC, Plastic, Extrusion

SPC Conical Twin Screw Production Line : This advanced flooring production line features a high-quality conical twin-screw extruder certified by CE/UL.

Key Points: 
  • SPC Conical Twin Screw Production Line : This advanced flooring production line features a high-quality conical twin-screw extruder certified by CE/UL.
  • With its intelligent electronic control system, power-saving capabilities, and high productivity, this flooring production line is ideal for manufacturing high-quality SPC flooring.
  • These advanced SPC flooring production lines incorporate innovative technologies and eco-friendly features, reflecting Boyu's commitment to sustainability and customer satisfaction.
  • "We are excited to participate in NPE2024 and demonstrate our cutting-edge SPC flooring production lines to a global audience," said Boyu's CEO, Mr. Lu.

Ostin Technology Group Unveils Strategic Expansion into North American Market With its US Subsidiary Begins Operation

Retrieved on: 
Wednesday, April 10, 2024
Tao, Life, Ecosystem

As part of its strategy to expand into the North American market with its new Pintura products, Pintura.Life recently launched a crowdfunding campaign on Indiegogo to help introduce Pintura to a broader U.S. and North American market, sparking interest among potential consumers and investors while evaluating the product’s market appeal.

Key Points: 
  • As part of its strategy to expand into the North American market with its new Pintura products, Pintura.Life recently launched a crowdfunding campaign on Indiegogo to help introduce Pintura to a broader U.S. and North American market, sparking interest among potential consumers and investors while evaluating the product’s market appeal.
  • The establishment of a prominent presence in San Francisco, U.S. reflects the Company's commitment to meet the escalating demand for its Pintura products in the North American region.
  • San Francisco, renowned as the hub of technological innovation in North America, emerged as the natural choice for the Company's expansion endeavors.
  • Embracing the city's vibrant tech ecosystem, the Company seeks to leverage local talents and seize the vast market opportunities presented by North America.

Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, March 29, 2024
Head, Immunotherapy, HNSCC, Patient, Roche, Lead, Immunoglobulin G, Neoplasm, CRC, Audit committee, PD-1, Observation, Bioinformatics, Colorectal cancer, SAN, Information technology, Pembrolizumab, PRS, Safety, PD-L1, Compensated emancipation, Annual report, Apoptosis, Cervical cancer, Part, Merck, Senior, Bevacizumab, MSS, GAAP, ASCO, PFS, MTD, Liver disease, HCC, Therapeutic index, Endometrial cancer, Progression-free survival, ADS, Net, Regulatory T cell, Research and development, Liver, Pharmaceutical industry

SAN DIEGO and SUZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today reported financial results for the full year 2023 and provided corporate updates.

Key Points: 
  • Both confirmed PRs are sustained after more than one year with repeat dosing while maintaining robust safety profiles.
  • Observation of these clinical activities triggered further expansion into the second stage of the Simon’s 2-stage design for this dose level.
  • Net loss attributable to Adagene Inc.’s shareholders was US$18.9 million for the year ended December 31, 2023, compared to US$80.0 million in 2022.
  • The company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure.

Ostin Technology Group Announces Indiegogo Crowdfunding Campaign Through its US Subsidiary to Elevate Pintura Photo Sharing Product Upgrade and Expand Global Sales Channels

Retrieved on: 
Thursday, March 21, 2024
Tao, Life, Research, Sale

The Company plans to launch an Indiegogo crowdfunding campaign by the end of March 2024, aiming to raise $300,000.

Key Points: 
  • The Company plans to launch an Indiegogo crowdfunding campaign by the end of March 2024, aiming to raise $300,000.
  • This campaign is set to elevate upgrade of its flagship photo-sharing product, Pintura, and to expand the Company’s global sales channels, thereby boosting brand recognition and market penetration.
  • The crowdfunding campaign is marking the Company’s strategic step towards entering the US market and underpinning the upgrade initiative for the Pintura product line.
  • Through the Indiegogo campaign, we invite backers to join us in bringing this transformative product to the market and expanding its global presence."

Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

Retrieved on: 
Thursday, March 7, 2024
SAN, Neoplasm, Division, Research fellow, Immunotherapy, Colorectal cancer, Gastrointestinal cancer, Drug development, Mentorship, Clinical research, Pembrolizumab, CRC, MSS, National Cancer Institute, FACP, Preventive healthcare, Gene expression, NCCN, USC, Associate, Patient, Harvard Medical School, Oncology, George Washington University, Cancer, Pharmaceutical industry

SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the “SAB”).

Key Points: 
  • SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the “SAB”).
  • Dr. Lenz accelerates translational and clinical research and provides training and mentoring in the design and implementation of investigator-initiated trials.
  • In 1991, he completed his internship, residency, and fellowship training at the Eberhardt Karls Universität in Tübingen, Germany.
  • “His insight and clinical experience as a leading expert in colorectal cancer is of great importance as we develop our SAFEbody® ADG126 for patients worldwide.”
    For more information about members of the Adagene Scientific and Strategic Advisory Board, visit: https://www.adagene.com/about/key-advisors/

Adagene to Present at the Leerink Partners Global Biopharma Conference 2024

Retrieved on: 
Tuesday, February 27, 2024
SAN, Conference

SAN DIEGO and SUZHOU, China, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in the Leerink Partners Global Biopharma Conference 2024, taking place March 11-13 in Miami, Florida.

Key Points: 
  • SAN DIEGO and SUZHOU, China, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in the Leerink Partners Global Biopharma Conference 2024, taking place March 11-13 in Miami, Florida.
  • Adagene’s Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will provide an update on its masked, anti-CTLA-4 SAFEbody® ADG126, including key milestones for 2024.
  • Company management will also host investor meetings.

Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stabl

Retrieved on: 
Friday, February 9, 2024
SAN, CRC, FDA, Part, MSS, Safety, Colorectal cancer, Pembrolizumab, Merck, Patient, CDE, Merck & Co., Pharmaceutical industry

SAN DIEGO and SUZHOU, China, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced progress and expansion of the clinical collaboration development program for its masked, anti-CTLA-4 SAFEbody, ADG126 in combination with Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with metastatic microsatellite-stable (MSS) colorectal cancer (CRC).

Key Points: 
  • Given the safety profile of ADG126, Adagene has also initiated evaluation of 20 mg/kg loading doses in combination with pembrolizumab in patients with advanced/metastatic cancer.
  • The company plans dose expansion with this regimen in patients with MSS CRC in the US and Asia Pacific.
  • Adagene has also received clearance from the CDE in China to initiate clinical evaluation of ADG126 in combination with pembrolizumab.
  • Data from the ongoing phase 1b/2 clinical trial of ADG126 in combination with pembrolizumab, including dose expansion cohorts, are anticipated throughout 2024:
    Evaluation of 20 mg/kg loading doses for Project Optimus requirements:

Ostin Technology Group Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Retrieved on: 
Wednesday, January 24, 2024
OST, Disclosure, Calendar

Nanjing, China, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. (the “Company”) (Nasdaq: OST), a supplier of display modules and polarizers in China, today announced that the Company had received a written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) dated January 19, 2024, indicating that for the last 30 consecutive business days, the closing bid price for the Company’s ordinary shares was below the minimum bid price of US$1.00 per share requirement set forth in Nasdaq Listing Rule 5550(a)(2).

Key Points: 
  • Nanjing, China, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. (the “Company”) (Nasdaq: OST), a supplier of display modules and polarizers in China, today announced that the Company had received a written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) dated January 19, 2024, indicating that for the last 30 consecutive business days, the closing bid price for the Company’s ordinary shares was below the minimum bid price of US$1.00 per share requirement set forth in Nasdaq Listing Rule 5550(a)(2).
  • This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.
  • The Nasdaq notification letter has no current effect on the listing or trading of the Company’s securities on the Nasdaq Capital Market, which will continue to trade uninterrupted on Nasdaq under the ticker "OST".
  • The Nasdaq notification letter will have no effect on the Company’s business operations, and the Company will take all reasonable measures to regain compliance.

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

Retrieved on: 
Tuesday, January 16, 2024
Endometrial cancer, Patient, Therapy, Associate, MD, City, MSS, SAN, Liver disease, ASCO, Merck & Co., Poster, Stage 2, Clinical research, Society, Research fellow, Immunotherapy, FACP, Cervical cancer, PRS, PFS, Safety, Liver, Observation, CRC, Pembrolizumab, NCCC, Merck, Physician, Oncology, Pharmaceutical industry

SAN DIEGO and SUZHOU, China, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced data from its presentation at the American Society of Clinical Oncology (ASCO) 2024 Gastrointestinal (GI) Cancers Symposium, taking place January 18-20 in San Francisco.

Key Points: 
  • “These promising data support further evaluation of this potential best-in-class anti-CTLA-4 antibody, ADG126, in combination with pembrolizumab for MSS CRC patients, including battling new liver lesions in those patients initially without detectable liver metastasis.
  • One of the patients had PD-1 refractory cervical cancer and the other had endometrial cancer.
  • The durable clinical activity of ADG126 in combination with pembrolizumab will continue to be evaluated as a larger cohort of subjects becomes evaluable at the 10 mg/kg Q3W dose level.
  • The clinical profile of ADG126 in combination with pembrolizumab presents a great opportunity for MSS CRC patients that otherwise have limited immunotherapy options available.”